Evozyne Announces $81 Million Financing Round to Advance Generative AI for Therapeutic Discovery and Drug Development
New investor OrbiMed expects platform to reduce development time for novel treatments and therapeutic approaches CHICAGO - BUSINESS WIRE, September 27, 2023 – Evozyne [...]
Harmony Biosciences to Acquire Zynerba Pharmaceuticals, Inc.
Acquisition expands pipeline and diversifies portfolio to drive long-term growth Innovative potential new therapeutic option for rare/orphan neuropsychiatric disorders with high unmet medical needs [...]
Harmony Biosciences Announces Jeffrey M. Dayno, M.D. Appointed President & Chief Executive Officer
– Dr. Dayno joins Harmony Biosciences Board of Directors – PLYMOUTH MEETING, PA, April 24, 2023 – Harmony Biosciences Holdings, Inc. (“Harmony” or the [...]
Emalex Biosciences Announces First Patient Dosed in Phase 3 Trial of Ecopipam for Tourette Syndrome
– Enrolled patients will receive medication for up to 24 weeks; 90 sites planned for North America and Europe – CHICAGO, March 1, 2023 [...]
Harmony Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
WAKIX® (pitolisant) Net Revenue Increased ~41% Year-over-Year to $128.3 Million for Fourth Quarter 2022; ~43% to $437.9 Million for Full Year 2022 Achieved Net [...]
Evozyne Creates AI Model with NVIDIA for Novel Protein Design, Expected to Accelerate Drug Development
– New AI model, co-developed by Evozyne and NVIDIA, can create novel therapeutic proteins for a new era of drug development – CHICAGO—January 12, [...]
